P/B
221
Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
$5B
Market Cap • 11/10/2026
2011
(15 years)
Founded
2003
(23 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
7,7
P/EBITDA
—
P/OCF
28,3
P/FCF
28,3
P/E
—
BVPS
0,2
EPS
—
Market Cap
Market Cap
5B
EV
5,1B
EV/Revenue
7,9
EV/EBITDA
-63,6
EV/EBIT
-38,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,8%
Total Yield
-1,8%
Payout
0%
Retained Earnings
-1,6B
Profitability
Gross Margin
98,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
37,7%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
41,2%
% PPE
1,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
24,1%
CAGR Op. Income 5Y
-10,6%
CAGR Net Income 5Y
-9,2%
CAGR EPS 5Y
-22,3%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3
Quick Ratio
2,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!